These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

660 related articles for article (PubMed ID: 15548365)

  • 1. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
    Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
    Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
    Song H; Kim J; Cosman D; Choi I
    Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
    Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
    Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
    Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
    FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell surface organization of stress-inducible proteins ULBP and MICA that stimulate human NK cells and T cells via NKG2D.
    Eleme K; Taner SB; Onfelt B; Collinson LM; McCann FE; Chalupny NJ; Cosman D; Hopkins C; Magee AI; Davis DM
    J Exp Med; 2004 Apr; 199(7):1005-10. PubMed ID: 15051759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
    Waldhauer I; Steinle A
    Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
    Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
    Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
    Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
    Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the NKG2D ligand UL16 binding protein-1 (ULBP-1) on dendritic cells.
    Schrama D; Terheyden P; Otto K; Kämmerer U; Bröcker EB; Lühder F; Cosman D; Andersen MH; Becker JC
    Eur J Immunol; 2006 Jan; 36(1):65-72. PubMed ID: 16342232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15.
    Sutherland CL; Rabinovich B; Chalupny NJ; Brawand P; Miller R; Cosman D
    Blood; 2006 Aug; 108(4):1313-9. PubMed ID: 16621962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cells in a HIF-1α-dependent manner.
    Yamada N; Yamanegi K; Ohyama H; Hata M; Nakasho K; Futani H; Okamura H; Terada N
    Int J Oncol; 2012 Dec; 41(6):2005-12. PubMed ID: 22992985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. UL16 binding proteins.
    Cao W; He W
    Immunobiology; 2004; 209(3):283-90. PubMed ID: 15518340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity.
    Maccalli C; Pende D; Castelli C; Mingari MC; Robbins PF; Parmiani G
    Eur J Immunol; 2003 Jul; 33(7):2033-43. PubMed ID: 12884870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Four novel ULBP splice variants are ligands for human NKG2D.
    Cao W; Xi X; Wang Z; Dong L; Hao Z; Cui L; Ma C; He W
    Int Immunol; 2008 Aug; 20(8):981-91. PubMed ID: 18544572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients.
    Salih HR; Goehlsdorf D; Steinle A
    Hum Immunol; 2006 Mar; 67(3):188-95. PubMed ID: 16698441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Expression and abscission of activated receptors and their ligands on/from NK cells in peripheral blood of patients with acute leukemia].
    Fang XC; Liu HL; Sun ZM; Gui L; Geng LQ; Wang XB; Zhou M; Wang ZY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):436-40. PubMed ID: 20416183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells.
    Sutherland CL; Chalupny NJ; Schooley K; VandenBos T; Kubin M; Cosman D
    J Immunol; 2002 Jan; 168(2):671-9. PubMed ID: 11777960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of the expression of MHC class I-related chain A, B (MICA, MICB) via chromatin remodeling and its impact on the susceptibility of leukemic cells to the cytotoxicity of NKG2D-expressing cells.
    Kato N; Tanaka J; Sugita J; Toubai T; Miura Y; Ibata M; Syono Y; Ota S; Kondo T; Asaka M; Imamura M
    Leukemia; 2007 Oct; 21(10):2103-8. PubMed ID: 17625602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
    Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
    J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor.
    Cosman D; Müllberg J; Sutherland CL; Chin W; Armitage R; Fanslow W; Kubin M; Chalupny NJ
    Immunity; 2001 Feb; 14(2):123-33. PubMed ID: 11239445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.